1. Hormone Receptor and c-ERBB2 Status in Distant Metastatic and Locally Recurrent Breast Cancer
- Author
-
Nan Soon Wong, Gary Man-Kit Tse, Philip C.W. Lui, Puay Hoon Tan, Poh Yian Cheok, Pushpalatha K.A. Idirisinghe, Stephanie Fook-Chong, and Aye Aye Thike
- Subjects
Oncology ,medicine.medical_specialty ,Pathology ,business.industry ,Estrogen receptor ,Cancer ,General Medicine ,medicine.disease ,Primary tumor ,Metastasis ,Breast cancer ,Internal medicine ,Progesterone receptor ,medicine ,Breast disease ,skin and connective tissue diseases ,Breast carcinoma ,business - Abstract
Estrogen receptor (ER), progesterone receptor (PR), and c-ERBB2 (HER2/neu) are therapeutically and prognostically important markers in the management of breast carcinoma. They are not always analyzed in distant metastatic and locally recurrent breast cancers. We compared immunohistochemical expression in a series of primary breast carcinomas with their distant metastases (n = 72) and local recurrences (n = 45) and analyzed the impact of any changes on survival. Discordance rates between primary and metastatic and between primary and locally recurrent lesions, respectively, were 18% (13/72) and 13% (6/45) for ER, 42% (30/72) and 33% (15/45) for PR, and 7% (5/72) and 2% (1/45) for c-ERBB2. There was statistically significant discordance between primary and metastatic PR status (P = .017; κ = 0.201). Among locally recurrent tumors, 15 (33%) of 45 revealed discordance for PR (P = .006; κ = 0.366). We observed a trend for shorter survival among women with ER– metastatic and locally recurrent tumors regardless of the primary tumor ER status. Our findings suggest a benefit for routine evaluation of ER, PR, and c-ERBB2 status in distant metastatic and locally recurrent breast cancer for therapeutic and prognostic purposes. Estrogen receptor (ER), progesterone receptor (PR), and c-ERBB2 (HER2/neu) are therapeutically and prognostically important markers in the management of breast carcinoma. About 60% to 70% of breast carcinomas express ER protein, and these tumors are associated with better prognosis. 1 Detecting ER expression in a tumor depends on physiologic and technical factors, including menopausal status, endocrine therapy, tumor sampling and intratumoral heterogeneity, tissue fixation, method of examination (biochemical, immunohistochemical), and type of antibody used. 2-4
- Published
- 2010
- Full Text
- View/download PDF